Investigational drug · Phase 3
Acotiamide
Also called: Itopride Hydrochloride
Not approved by FDA. In 2 industry-sponsored Phase 2 or 3 trials that are active or finished in the last two years, most often for Postprandial Distress Syndrome, Functional Dyspepsia.
Phase 3Last checked: Nov 19, 2026Latest source record: Apr 3, 2026 (newest trial update)Source: ClinicalTrials.govMethods & limitations
Highest phase
Phase 3
Industry-sponsored trials
Phase 2 and 3 trials
2
1 still active
All registered trials
15
Any phase or sponsor naming "Acotiamide"
First trial start
2024
Feb 28, 2024
Sponsors
Lead sponsors of its Phase 2 and 3 trials.
All registered trials by phase
Every ClinicalTrials.gov drug study naming "Acotiamide", any sponsor or status.
Conditions studied
As listed on its trial records.
- Postprandial Distress Syndrome
- Functional Dyspepsia
Approved drugs for the same conditions: Rare and genetic disease
Largest trials
Live from ClinicalTrials.gov: studies naming "Acotiamide" as an intervention, largest first.
- To Verify the Efficacy of Z-338 in Subjects With Functional DyspepsiaPivotal-lookingCompleted
Zeria PharmaceuticalIndustry
NCT00761358 · 820 participants (planned) · Start Sep 2008 · Primary completion Jun 2010
Drug: Z-338; Placebo · For: Functional Dyspepsia
Sites: Hokkaido, Japan; Tokyo, Japan
- To Evaluate the Efficacy of Z-338 in Subjects With Functional DyspepsiaPivotal-lookingCompleted
Zeria PharmaceuticalIndustry
NCT00333372 · 440 participants · Start Apr 2006
Drug: Z-338 · For: Functional Dyspepsia
Sites: Sendai, Japan
- YM443 in Subjects With Functional DyspepsiaPivotal-lookingCompleted
Astellas Pharma IncAstellas (ALPMY)
NCT00102310 · 416 participants · Start Mar 10, 2004 · Primary completion Mar 11, 2006
Drug: YM443 · For: Indigestion; Nausea
Sites: Huntsville, Alabama; Little Rock, Arkansas; Anaheim, California · 59 sites in all
- A Long-term, Open-label, Uncontrolled Trial of YM443 (Z-338) in Patients With Functional DyspepsiaPivotal-lookingCompleted
Astellas Pharma IncAstellas (ALPMY)
NCT00764374 · 412 participants · Start Aug 2008 · Primary completion Dec 2009
Drug: YM443 · For: Dyspepsia; Functional Dyspepsia
Sites: Hokkaido, Japan; Kansai, Japan; Kantou, Japan · 4 sites in all
- Comparing Acotiamide and Itopride for the Management of IndigestionPivotal-lookingNot yet recruiting
Aga Khan UniversityAcademic, hospital or other
NCT07449689 · 368 participants (planned) · Start Apr 2026 · Primary completion Dec 2026
Drug: Acotiamide; itopride · For: Functioanl Dyspepsia; Post Prandial Distress Syndrome
- To Evaluate the Efficacy and Safety in Subjects With Functional DyspepsiaPivotal-lookingCompleted
Zeria PharmaceuticalIndustry
NCT00323817 · 282 participants (planned) · Start Apr 2006 · Primary completion Apr 2009
Drug: Z-338 · For: Functional Dyspepsia
Sites: Leuven, Belgium
- Phase III, Long-term, Open-label Safety Study of Z-338Pivotal-lookingCompleted
Zeria PharmaceuticalIndustry
NCT01973790 · 207 participants · Start Mar 2014 · Primary completion Nov 2016
Drug: Z-338 · For: Dyspepsia
Sites: Leuven, Belgium; Plovdiv, Bulgaria; Sofia, Bulgaria · 36 sites in all
- Helicobacter Pylori Eradication in Functional DyspepsiaPivotal-lookingCompleted
Sir Ganga Ram HospitalAcademic, hospital or other
NCT04697641 · 202 participants · Start Sep 1, 2017 · Primary completion May 31, 2019
Drug: Clarithromycin 500mg; Amoxicillin 1000 MG and 4 more · For: Dyspepsia; Helicobacter Pylori Infection
Sites: New Delhi, India
- Acotiamide vs Itopride in Postprandial Distress SyndromePivotal-lookingNot yet recruiting
Getz PharmaIndustry
NCT07174297 · 152 participants (planned) · Start Oct 30, 2025 · Primary completion Dec 30, 2026
Drug: Acotiamide · For: Postprandial Distress Syndrome
Astellas Pharma IncAstellas (ALPMY)
NCT00850746 · 80 participants · Start Feb 2009 · Primary completion Apr 2009
Drug: YM443; Placebo and 1 more · For: Functional Dyspepsia
Sites: Tacoma, Washington
Newest research
PubMed records naming it or its code names, newest first.
- Pioneering Novel, Green, White, and Blue Fluorescence-Based Platforms for Sustainable and Concurrent Monitoring of Ciprofloxacin With Celecoxib or Itopride in Biological Matrices.
Barakat NT, El-Aziz HA, Eid MI, et al. · Luminescence 2026
- RETRACTED: Badr et al. Design and Evaluation of S-Protected Thiolated-Based Itopride Hydrochloride Polymeric Nanocrystals for Functional Dyspepsia: QbD-Driven Optimization, In Situ, In Vitro, and In Vivo Investigation. Pharmaceuticals 2023, 16, 925.
Badr MY, Basim P, Hosny KM, et al. · Pharmaceuticals (Basel) 2026
- Efficacy and safety of acotiamide in esophagogastric junction outflow obstruction: a placebo-controlled phase II trial.
Ihara E, Ogino H, Esaki M, et al. · Esophagus 2026
- Optimization and evaluation of gastro-expandable film of Eudragit S100 and ethylcellulose by using the design of experiment.
Dass R, Rani P, Verma V, et al. · Sci Rep 2026
- Impact of itopride on functional dyspepsia symptom progression: a multicenter noninterventional postregistration study.
Dolina J, Tack J, Forostyak S, et al. · Ther Adv Gastroenterol 2026
- Quality by design approach for optimization, in-vitro and in-vivo evaluation of compression-spheronized itopride hydrochloride loaded gastroretentive pellets for the treatment of gastroesophageal reflux disease.
Dass R, Rani P, Kumar D, et al. · Naunyn Schmiedebergs Arch Pharmacol 2026
Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.